Last updated on December 2019

A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Brief description of study

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

Detailed Study Description

This study is designed to evaluate the efficacy and safety of TD139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. Subjects will continue on their existing standard of care (SoC), including pirfenidone or nintedanib. Two doses of TD139, each given once per day, will be compared to placebo. A follow up period of up to 52 weeks, where the subjects remain on their designated treatment, will provide valuable information on the longer-term safety of TD139 in IPF.

Clinical Study Identifier: NCT03832946

Find a site near you

Start Over

Broward Research Center

Pembroke Pines, FL United States
  Connect »